RESEARCH CONTEXT ONLY
Thymulin Dosage in Research: Routes, Doses, and Pharmacokinetics
Thymulin has been studied across multiple rodent models using intraperitoneal, intracerebroventricular, and intratracheal routes. No human clinical dosing data exists — no Phase 1, 2, or 3 trials of exogenous Thymulin administration in humans have been published. The figures below are research context only: what was administered to which species at which dose in which study.
Important: Nothing on this page constitutes dosing guidance for humans. These are species-specific preclinical research doses only.
RESEARCH DOSE TABLE
Thymulin Dosage in Published Research
Research doses vary substantially by model and endpoint. Representative examples from the peer-reviewed record:
| Study | Species | Dose | Route | Endpoint |
|---|---|---|---|---|
| Lunin et al., 2008[12] | Mouse (NMRI) | 15 µg/100 g | i.p. | Pro-inflammatory cytokine suppression (LPS model) |
| Novoselova et al., 2014[13] | Mouse (BALB/c) | 1.5 mg/kg | i.p. | NF-kappaB inhibition; TNF-alpha/IFN-gamma reduction |
| Novoselova et al., 2018[19] | Mouse (BALB/c) | 1.5 mg/kg (free) | i.p. | Chronic septic inflammation protection |
| Lunin et al., 2015[18] | Mouse (C57BL/6) | 0.15 mg/kg every other day | i.p. | EAE disease severity reduction |
| Safieh-Garabedian et al., 2002[15] | Rat (Sprague-Dawley) | 25–50 µg | i.p. | Analgesic, anti-inflammatory (PAT analog) |
| Nasseri et al., 2019[14] | Rat (CFA model) | Research doses | i.p. | Thermal hyperalgesia; spinal microglial inhibition |
| Haddad and Hanbali, 2013[17] | Rat | 1–25 µg (dose-dependent) | i.c.v. | NF-kappaB inhibition in hippocampus |
| Hadley et al., 1997[23] | Rat pituitary (in vitro) | 0.5–50 pM (optimal 10 pM) | In vitro | ACTH release; cAMP/cGMP elevation |
| Oliver and Marsh, 2003[11] | Avian (chicken) | Various; 50 ng/100g suppressive | Injection | NK cell cytotoxicity (biphasic dose response) |
Note on gene therapy doses: Gene therapy vector doses are expressed in viral genome copies per kilogram body weight and are not comparable to peptide doses above. Reggiani et al. demonstrated sustained thymulin expression for 112+ days at adenoviral vector doses in rodent models;[21] Science Advances (2020) used CK30PEG DNA nanoparticles for intratracheal delivery.[26] These are distinct research programs from exogenous peptide administration.
PHARMACOKINETICS
Pharmacokinetic Profile
Thymulin's plasma half-life is approximately 10 minutes in rodent models.[19] This very short half-life reflects peptide degradation and limits the utility of native thymulin administration — a finding that has motivated research into alternative delivery approaches.
The zinc-free apothymulin is biologically inactive. Zinc binding is required for receptor activity; zinc chelation abolishes it reversibly.[1] Alpha-2-macroglobulin can compete with thymulin for zinc binding even when total plasma zinc appears normal — creating functional Zn-thymulin deficit in conditions of elevated alpha-2-macroglobulin (Mocchegiani et al., 1999).[10]
Circadian variation: thymulin follows a circadian rhythm with peak serum levels at approximately 1:00 a.m. in rodent studies.[23][24] This is relevant to study design — blood sampling time affects measured thymulin values in observational research.
No validated human pharmacokinetic data has been published.
ADMINISTRATION ROUTES
Routes Studied
Across the published record, thymulin has been administered via:
- Intraperitoneal — most common in rodent studies; used in cytokine suppression, EAE, and analgesic experiments[12][13][18][19]
- Intracerebroventricular — CNS neuroprotection and NF-kappaB hippocampal studies[17]
- Intratracheal — lung/asthma gene therapy nanoparticle delivery[26]
- In vitro — pituitary ACTH stimulation, PBMC, macrophage experiments[4][23]
- Subcutaneous — referenced in pharmacokinetic overviews; less common
- Nanoparticle-bound — PBCA nanoparticles studied as a half-life extension strategy[19][27]
- Gene therapy vector — adenoviral and CK30PEG nanoparticle delivery of synthetic metFTS gene[20][21][26]
No oral thymulin administration studies have been identified in the reviewed literature. The peptide's short half-life and structural sensitivity to proteolytic degradation make oral bioavailability a concern not yet studied.
ADVANCED DELIVERY
Delivery System Research: Addressing the 10-Minute Half-Life
The ~10-minute plasma half-life is the central pharmacokinetic limitation. Two research approaches address it:
PBCA nanoparticles. Thymulin bound to polybutylcyanoacrylate nanoparticles demonstrated superior efficacy versus free thymulin in chronic septic inflammation mice (Novoselova et al., 2018, PLOS ONE)[19] and in relapsing-remitting EAE models — with complete recovery observed in some animals (Novoselova et al., 2019, IJMS).[27] The mechanism is extended bioavailability: nanoparticle encapsulation slows degradation and sustains effective plasma levels.
Gene therapy. Adenoviral vector delivery of synthetic metFTS (methionine-FTS) achieved sustained biologically active thymulin expression for 112+ days in rodent models.[21] DNA nanoparticle (CK30PEG) delivery resolved experimental allergic asthma pathology within 20 days following a single intratracheal dose.[26] Gene therapy eliminates the half-life problem by enabling continuous endogenous-level expression.
Both approaches remain pre-clinical. No human trials have been conducted.
SAFETY PROFILE
Safety and Adverse Effects in the Research Record
Pre-clinical literature reports minimal acute toxicity at studied doses in rodent models. The PAT analog study (Safieh-Garabedian et al., 2002) reported no significant adverse effects at 25–50 µg i.p. in rats across multiple nociceptive tests, with comparable safety to reference anti-inflammatory agents.[15]
Two theoretical concerns noted in the research literature:
- Immunostimulatory compounds carry a theoretical autoimmune risk. No robust animal data demonstrates autoimmune induction by thymulin at research doses; the EAE studies show anti-inflammatory effects rather than worsening.[18][27] This remains a theoretical concern requiring characterization in longer-term studies.
- Biphasic dose-response on pain signaling. At nanogram-range doses, thymulin may be pro-nociceptive (PGE2-mediated); at microgram doses it is analgesic. This biphasic profile is well-documented[25] and is a research-design consideration, not a clinical safety observation.
No human safety data exists. No thymulin dosage in research has been validated for human administration.